ImmuCell Announces Product Sales Increases and Other Financial Results
(firmenpresse) - PORTLAND, ME -- (Marketwire) -- 02/14/13 -- (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2012.
"Despite the ongoing economic hardships faced by our customers, we ended the year with strong product sales in the fourth quarter. Sales of our lead product, ®, increased by 16% and 5% during the fourth quarter and for the full year, respectively, over 2011 levels," commented Michael F. Brigham, President and CEO. "As projected, our bottom line performance improved from a loss in 2011 to a profit in 2012."
During the three-month period ended December 31, 2012, product sales increased by 9%, or $116,000, to $1,421,000 in comparison to the same period in 2011. During the year ended December 31, 2012, product sales increased by 5.5%, or $279,000, to $5,390,000 in comparison to 2011.
The net operating income was $245,000 during the year ended December 31, 2012, in contrast to a net operating loss of ($633,000) during 2011. The net income was $90,000, or $0.03 per share, during the year ended December 31, 2012, in contrast to a net loss of ($410,000), or ($0.14) per share, for 2011. The improved financial performance is principally due to planned reductions in product development expenses associated with the ® product development initiative, as well as increased gross margin from sales of ®. The Company remains actively engaged in pursuing the necessary financing to complete the ® initiative.
Cash, cash equivalents and short-term investments decreased by less than 1%, or $46,000, to $4,914,000 at December 31, 2012 as compared to $4,960,000 at December 31, 2011. Stockholders' equity increased by 2%, or $174,000, to $9,195,000 at December 31, 2012 as compared to $9,020,000 at December 31, 2011. The Company had 3,019,000 shares of common stock outstanding as of December 31, 2012.
About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, ().
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.02.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 1197046
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PORTLAND, ME
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 78 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ImmuCell Announces Product Sales Increases and Other Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
ImmuCell Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
